Loading provider…
Loading provider…
Hematology & Oncology Physician in Maywood, IL
NPI: 1013994086Primary Practice Location
Loyola University Medical Center
2160 S 1st Ave, IL
Primary Employer
Rush University Internists
rush.edu
HQ Phone
Get MD Shelly's Phone Numberphone_androidMobile
Get MD Shelly's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
IL State Medical License
2004 - 2026
PA State Medical License
2002 - 2004

American Board of Internal Medicine
Hospice and Palliative Medicine

American Board of Internal Medicine
Medical Oncology
UPMC Medical Education
Fellowship • Hematology and Medical Oncology
2002 - 2004
Albany Medical Center
Residency • Internal Medicine/Pediatrics
1997 - 2001
Icahn School Of Medicine At Mount Sinai
icahn.mssm.edu
Fellowship • Hematology and Medical Oncology
2001 - 2002
SUNY Upstate Medical University
upstate.edu
Medical School
Until 1997
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 134 | 145 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 60 | 87 |
Body Composition, Serum Biomarkers of Inflammation and Quality of Life in Clinically Stable Women with Estrogen Receptor Positive Metastatic Breast Cancer
Authors: Patricia M. Sheean, Sandra L. Gomez-Perez, Cara Joyce, Vasilios Vasilopoulos, Mary Beth Bartolotta, Patricia A. Robinson, Shelly S. Lo, Laurie M Lomasney
Publication Date: 2019-04
Impact of multigene assays in early stage breast cancer.
Authors: Lo, Shelly S, Albain, Kathy S
Journal: Oncologist
Publication Date: 2011-10-20
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Placebo, DRUG: Dexamethasone, DRUG: Olanzapine, DRUG: Palonosetron Hydrochloride, DRUG: Ondansetron Hydrochloride, DRUG: Fosaprepitant Dimeglumine
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Carboplatin, OTHER: Laboratory Biomarker Analysis, DRUG: Cyclophosphamide, DRUG: Paclitaxel, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: Halozyme Therapeutics
Intervention / Treatment: DRUG: Enoxaparin, DRUG: Dexamethasone, DRUG: Gemcitabine, DRUG: Nab-paclitaxel, DRUG: PEGPH20